publication date: Nov. 17, 2017
Issue 43 - Nov. 17, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Defining the next level for Inova

    In 2010, John Knox Singleton, the CEO of the Inova Health System, had several meetings with John Niederhuber, a surgeon and scientist who had just been replaced as NCI director.

    At the time, Niederhuber still had a lab at NIH, but was plotting the next step in his career. Singleton had been Inova’s CEO since 1984.

  • Caligiuri resigns as CEO of the James after stepping down as director of OSUCCC

    Michael Caligiuri, who over the past 14 years demonstrated virtuosity in recruitment, lobbying, and fundraising, building the third-largest cancer hospital in the U.S., has stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

  • An Appreciation

    Hail to “The Chief” Donald S. Coffey, a scientist, a mentor, a wit, dies at 85

    Donald S. Coffey, Ph.D., cancer warrior, humanist, mentor to hundreds of researchers and physicians, friend to countless people, was filled with a burning curiosity to understand the world and to know personally everyone he came in contact with.

    Everyone has the story—“I met Don at a meeting and he sat me down and he asked me to tell him my life story—and I was forever changed.”

  • In Brief

    • De la Chapelle receives lifetime achievement award from colorectal cancer group
    • Gallagher named vice president and head of Global Oncology Development at AbbVie 
    • Sylvester geneticist Shiekhattar receives NIH “Pioneer Award” 
    • WPI’s Mattson receives $1.7-million NIH award to develop molecular methods
    • LUNGevity partners with ALK Positive Patient Group to fund research
  • Drugs and Targets

    • FDA approves adjuvant indication for Sutent in renal cell carcinoma
    • FDA approves obinutuzumab for previously untreated follicular lymphoma
    • FDA approves Sprycel for pediatric patients with CML
    • FDA approves Genentech’s Hemlibra to prevent bleeding in hemophilia A
    • FDA authorized MSKCC’s tumor profiling tests

Copyright (c) 2017 The Cancer Letter Inc.